Latest Strategy Changes News

Lendlease has partnered with The Crown Estate to form the Impact Partnership Joint Venture, unlocking a £24 billion UK development pipeline including up to 30,000 new homes and nearly a million square metres of office and life sciences space.

Black Rock Mining has secured an extension of its US$204 million debt facility to November 2026, providing more time to finalise equity funding for the Mahenge Graphite Project in Tanzania.

Objective Corporation loses a longstanding Department of Defence support contract, impacting future recurring revenue but maintaining a commitment to sovereign tech innovation.

Alara Resources has dispatched its 51st copper concentrate shipment from Oman’s Al Wash-hi Majaza mine, delivering over 7,200 tonnes of contained copper for the 2026 financial year.

Kinetiko Energy has approved a Field Development Plan marking its shift from exploration to production at the Brakfontein gas project in South Africa, aiming to fast-track gas output and secure strategic funding.

Nido Education Limited has secured a 12-month extension on its NAB loan facility, increasing available funding by $10 million and raising its bank guarantee capacity to $17.5 million, underpinning its growth in early childhood education.

Norwest Minerals updates its Bulgera Gold Project resource estimate to 191,000 ounces within an optimised open-pit shell, underpinning a promising heap leach development pathway with strong metallurgical recoveries.

DXN Limited has landed a $1 million contract to deliver a Cable Landing Station in American Samoa, reinforcing its foothold in Pacific telecom infrastructure while divesting a non-core Tasmanian data centre.

Global X Management (AUS) Limited is trimming the management fee for its Australia 300 ETF (ASX: A300) by 25%, effective 1 July 2026, reflecting a subtle but meaningful cost saving for investors.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

Beetaloo Energy reports promising flow testing from Carpentaria-5H with sustained gas rates and low decline, while its Carpentaria Gas Plant construction remains on schedule for first gas sales in late 2026.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.